264 related articles for article (PubMed ID: 1543025)
1. Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal.
Sadoul JL; Thyss A; Freychet P
Acta Endocrinol (Copenh); 1992 Feb; 126(2):179-83. PubMed ID: 1543025
[TBL] [Abstract][Full Text] [Related]
2. Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201-995).
Warnet A; Lajeunie E; Gelbert F; Duet M; Chanson P; Cophignon J; Harris AG
Acta Endocrinol (Copenh); 1991 Apr; 124(4):487-91. PubMed ID: 2031445
[TBL] [Abstract][Full Text] [Related]
3. Bromocriptine treatment of prolactin-secreting pituitary adenomas may restore pituitary function.
Warfield A; Finkel DM; Schatz NJ; Savino PJ; Snyder PJ
Ann Intern Med; 1984 Dec; 101(6):783-5. PubMed ID: 6497193
[TBL] [Abstract][Full Text] [Related]
4. Desensitization to somatostatin analogue (Octreotide) observed in a patient with acromegaly.
Haraguchi K; Ohtaka M; Takazawa K; Endo T; Onaya T
Endocr J; 1995 Apr; 42(2):295-300. PubMed ID: 7627275
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
[TBL] [Abstract][Full Text] [Related]
6. The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex.
van der Lely AJ; Harris AG; Lamberts SW
Clin Endocrinol (Oxf); 1992 Aug; 37(2):181-5. PubMed ID: 1395069
[TBL] [Abstract][Full Text] [Related]
7. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy.
Plöckinger U; Reichel M; Fett U; Saeger W; Quabbe HJ
J Clin Endocrinol Metab; 1994 Nov; 79(5):1416-23. PubMed ID: 7962337
[TBL] [Abstract][Full Text] [Related]
8. The medical treatment of prolactin and growth hormone-secreting pituitary tumours.
Lancranjan I
Acta Neurochir Suppl (Wien); 1990; 47():71-85. PubMed ID: 1968311
[No Abstract] [Full Text] [Related]
9. Long-term in-vitro treatment of human growth hormone (GH)-secreting pituitary adenoma cells with octreotide causes accumulation of intracellular GH and GH mRNA levels.
Hofland LJ; Velkeniers B; vd Lely AJ; van Koetsveld PM; Kazemzadeh M; Waaijers M; Hooghe-Peters EL; Lamberts SW
Clin Endocrinol (Oxf); 1992 Sep; 37(3):240-8. PubMed ID: 1424206
[TBL] [Abstract][Full Text] [Related]
10. Bromocriptine-induced changes in hormone secretion and cell morphology in growth hormone and prolactin producing pituitary adenomas.
Anniko M; Werner S; Wersäll J
Acta Otolaryngol; 1981; 92(3-4):343-55. PubMed ID: 7324902
[No Abstract] [Full Text] [Related]
11. Pathological study of thyrotropin-secreting pituitary adenoma: plurihormonality and medical treatment.
Teramoto A; Sanno N; Tahara S; Osamura YR
Acta Neuropathol; 2004 Aug; 108(2):147-53. PubMed ID: 15185102
[TBL] [Abstract][Full Text] [Related]
12. Bromocriptine reduces the size of cells in prolactin-secreting pituitary adenomas.
Landolt AM; Minder H; Osterwalder V; Landolt TA
Experientia; 1983 Jun; 39(6):625-6. PubMed ID: 6852202
[TBL] [Abstract][Full Text] [Related]
13. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre.
Abe T; Lüdecke DK
Eur J Endocrinol; 2001 Aug; 145(2):137-45. PubMed ID: 11454508
[TBL] [Abstract][Full Text] [Related]
14. Effect of bromocriptine on DNA synthesis, growth and hormone secretion of spontaneous pituitary tumours in the rat.
Prysor-Jones RA; Jenkins JS
J Endocrinol; 1981 Mar; 88(3):463-9. PubMed ID: 7217831
[TBL] [Abstract][Full Text] [Related]
15. Clinical and morphological findings in two cases of bromocriptine-treated prolactinomas.
Anniko M; Wersäll J
Acta Pathol Microbiol Scand A; 1981 Jan; 89(1):41-7. PubMed ID: 7223426
[TBL] [Abstract][Full Text] [Related]
16. Long-term treatment with bromocriptine of a plurihormonal pituitary adenoma secreting thyrotropin, growth hormone and prolactin.
Shimatsu A; Murabe H; Nakamura Y; Mizuta H; Ihara C; Nakao K
Endocr J; 1999 Feb; 46(1):159-65. PubMed ID: 10426581
[TBL] [Abstract][Full Text] [Related]
17. [A case of thyrotropin-, growth hormone-, and prolactin-secreting pituitary adenoma with a remarkable response to long-acting somatostatin analogue (SMS201-995)].
Usui T; Sako Y; Matsumoto M; Kita T; Shimatsu A; Imura H
Nihon Naika Gakkai Zasshi; 1989 Nov; 78(11):1605-6. PubMed ID: 2614206
[No Abstract] [Full Text] [Related]
18. Enlargement of a prolactin-secreting pituitary microadenoma during bromocriptine treatment. Case report.
Crosignani PG; Mattei A; Ferrari C; Giovanelli MA
Br J Obstet Gynaecol; 1982 Feb; 89(2):169-70. PubMed ID: 7066250
[TBL] [Abstract][Full Text] [Related]
19. A comparison between the effects of SMS 201-995, bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients.
Lamberts SW; Verleun T; Hofland L; Del Pozo E
Clin Endocrinol (Oxf); 1987 Jul; 27(1):11-23. PubMed ID: 2888550
[TBL] [Abstract][Full Text] [Related]
20. Reduction of pituitary-tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy.
Wass JA; Moult PJ; Thorner MO; Dacie JE; Charlesworth M; Jones AE; Besser GM
Lancet; 1979 Jul; 2(8133):66-9. PubMed ID: 87966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]